Bladder Cancer Clinical Trials
Bladder Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for bladder Cancer. Corterve aggregates actively recruiting Bladder Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Bladder Cancer studies
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialNCT06770582PHASE2National Cancer Institute (NCI)Fayetteville, Arkansas
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialNCT07061964PHASE2National Cancer Institute (NCI)Birmingham, Alabama
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyNCT05756569PHASE2Emory UniversityAtlanta, Georgia
- A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)NCT06929286PHASE3Memorial Sloan Kettering Cancer CenterBaltimore, Maryland
- Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2NCT07225127University of WashingtonTampa, Florida
- Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsNCT06963346PHASE1H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382PHASE2National Cancer Institute (NCI)Birmingham, Alabama
- Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsNCT07660055PHASE1Novartis PharmaceuticalsOmaha, Nebraska
- A Study of a Side Effects and Resource Navigation Program for People With CancerNCT07646847NAMemorial Sloan Kettering Cancer CenterBasking Ridge, New Jersey
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)NCT07419295PHASE3Merck Sharp & Dohme LLCTraverse City, Michigan
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069PHASE1Eli Lilly and CompanyDuarte, California
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaNCT07129993PHASE2, PHASE3Daiichi SankyoFullerton, California
Bladder Cancer trials by state
Bladder Cancer trials by metro
Frequently asked questions
- How do I find recruiting Bladder Cancer clinical trials?
- Corterve aggregates actively recruiting Bladder Cancer studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Bladder Cancer clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Bladder Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.